Metacell sits at the intersection of two megatrends: pharma's push to secure its supply chain, and synthetic biology's rise as an industrial platform.
We’ve built the technical foundation. Now we’re scaling it.
Two ways
The global fermentation-derived API market is large, established, and worth billions annually. Yet most manufacturers are leaving margin on the table — yields are suboptimal, strain development is slow, and the economics of complex API production remain unnecessarily tight.
Metacell closes that gap.
Screening millions of mutants at speed, in filamentous systems, for complex APIs — that's not something a competitor builds in a year. It requires deep biological expertise, proprietary workflows, and a platform validated through years of development.
We have it. They don't.
A University of Turku spin-out.
Turun yliopiston spin-out-yritys.
Ett avknoppningsföretag från Åbo universitet.
© 2026 Metacell Oy. Created with 